These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31729103)

  • 1. Correlation of pre-operative circulating inflammatory cytokines with restenosis and rapid angiographic stenotic progression risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents.
    Sun J; Yu H; Liu H; Pu D; Gao J; Jin X; Liu X; Yan A
    J Clin Lab Anal; 2020 Mar; 34(3):e23108. PubMed ID: 31729103
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential of circulating pro-angiogenic microRNA expressions as biomarkers for rapid angiographic stenotic progression and restenosis risks in coronary artery disease patients underwent percutaneous coronary intervention.
    Dai R; Liu Y; Zhou Y; Xiong X; Zhou W; Li W; Zhou W; Chen M
    J Clin Lab Anal; 2020 Jan; 34(1):e23013. PubMed ID: 31495986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive analysis of predictive factors for rapid angiographic stenotic progression and restenosis risk in coronary artery disease patients underwent percutaneous coronary intervention with drug-eluting stents implantation.
    Wu Y; Fu X
    J Clin Lab Anal; 2019 Feb; 33(2):e22666. PubMed ID: 30221497
    [TBL] [Abstract][Full Text] [Related]  

  • 4. miR-146a and miR-146b predict increased restenosis and rapid angiographic stenotic progression risk in coronary heart disease patients who underwent percutaneous coronary intervention.
    Zhang H; Zhang Q; Liu Y; Xue T
    Ir J Med Sci; 2020 May; 189(2):467-474. PubMed ID: 31680203
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGF-23 correlates with endocrine and metabolism dysregulation, worse cardiac and renal function, inflammation level, stenosis degree, and independently predicts in-stent restenosis risk in coronary heart disease patients underwent drug-eluting-stent PCI.
    Song T; Fu Y; Wang Y; Li W; Zhao J; Wang X; Wang H; Zhao Y; Fu X
    BMC Cardiovasc Disord; 2021 Jan; 21(1):24. PubMed ID: 33413149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term clinical and angiographic outcomes of percutanenous coronary intervention with everolimus-eluting stents for the treatment of cardiac allograft vasculopathy.
    Cheng R; Vanichsarn C; Patel JK; Currier J; Chang DH; Kittleson MM; Makkar R; Kobashigawa JA; Azarbal B
    Catheter Cardiovasc Interv; 2017 Jul; 90(1):48-55. PubMed ID: 27862865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between uric acid to albumin ratio and in-stent restenosis in patients with coronary artery disease undergoing drug-eluting stenting.
    Liu W; Ding K; Bao J; Hu Y; Gui Y; Ye L; Wang L
    Coron Artery Dis; 2023 Dec; 34(8):589-594. PubMed ID: 37855441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel Biomarkers for Coronary Restenosis Occurrence After Drug-Eluting Stent Implantation in Patients With Diabetes Having Stable Coronary Artery Disease.
    Gabbasov Z; Kozlov S; Melnikov I; Byazrova S; Saburova O; Prokofieva L; Caprnda M; Curilla E; Gaspar L; Rodrigo L; Kruzliak P; Smirnov V
    Clin Appl Thromb Hemost; 2018 Nov; 24(8):1308-1314. PubMed ID: 29716394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison between catheter-based delivery of paclitaxel after bare-metal stenting and drug-eluting stents in coronary artery disease patients at high risk for in-stent restenosis.
    El-Mokadem M; El-Ramly M; Hassan A; Boshra H; AbdelWahab A
    Cardiovasc Revasc Med; 2017 Dec; 18(8):596-600. PubMed ID: 28625402
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood level of CD45+ platelets and development of restenosis after drug-eluting stent implantation in patients with stable coronary artery disease.
    Gabbasov Z; Kozlov S; Byazrova S; Saburova O; Melnikov I; Caprnda M; Curilla E; Gaspar L; Kruzliak P; Smirnov V
    Wien Klin Wochenschr; 2016 Dec; 128(23-24):898-905. PubMed ID: 27637207
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Three- and 6-month optical coherence tomographic surveillance following percutaneous coronary intervention with the Angiolite® drug-eluting stent: The ANCHOR study.
    Puri R; Otaegui I; Sabaté M; Serra-Peñaranda A; Puigfel M; Perez de Prado A; Nombela-Franco L; de la Torre Hernandez JM; Ortas Nadal R; Iniguez-Romo A; Jiménez G; Fernandez-Vazquez F; Cuellas-Ramon C; Gonzalo N; Alfonso Jiménez Diaz V; Duocastella L; Molina M; Amoros M; Perez I; Barria Perez A; Pelletier Beaumont E; Nicholls SJ; Garcia Del Blanco B; Rodés-Cabau J
    Catheter Cardiovasc Interv; 2018 Feb; 91(3):435-443. PubMed ID: 28707379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A prediction model based on platelet parameters, lipid levels, and angiographic characteristics to predict in-stent restenosis in coronary artery disease patients implanted with drug-eluting stents.
    Gai MT; Zhu B; Chen XC; Liu F; Xie X; Gao XM; Ma X; Fu ZY; Ma YT; Chen BD
    Lipids Health Dis; 2021 Sep; 20(1):118. PubMed ID: 34587955
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase of VEGF plasma levels is associated with restenosis of drug-eluting stents.
    Katsaros KM; Kastl SP; Krychtiuk KA; Hutter R; Zorn G; Maurer G; Huber K; Wojta J; Christ G; Speidl WS
    EuroIntervention; 2014 Jun; 10(2):224-30. PubMed ID: 24168783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A clinical and angiographic study of the XIENCE V everolimus-eluting coronary stent system in the treatment of patients with multivessel coronary artery disease: the EXECUTIVE trial (EXecutive RCT: evaluating XIENCE V in a multi vessel disease).
    Ribichini F; Romano M; Rosiello R; La Vecchia L; Cabianca E; Caramanno G; Milazzo D; Loschiavo P; Rigattieri S; Musarò S; Pironi B; Fiscella A; Amico F; Indolfi C; Spaccarotella C; Bartorelli A; Trabattoni D; Della Rovere F; Rolandi A; Beqaraj F; Belli R; Sangiorgio P; Villani R; Berni A; Sheiban I; Lopera Quijada MJ; Cappi B; Ribaldi L; Vassanelli C;
    JACC Cardiovasc Interv; 2013 Oct; 6(10):1012-22. PubMed ID: 24055444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining clinical and angiographic variables for estimating risk of target lesion revascularization after drug eluting stent placement.
    Stolker JM; Cohen DJ; Kennedy KF; Pencina MJ; Arnold SV; Kleiman NS; Spertus JA;
    Cardiovasc Revasc Med; 2017; 18(3):169-176. PubMed ID: 28041858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Everolimus-Eluting Stents in Patients With Bare-Metal and Drug-Eluting In-Stent Restenosis: Results From a Patient-Level Pooled Analysis of the RIBS IV and V Trials.
    Alfonso F; Pérez-Vizcayno MJ; García Del Blanco B; García-Touchard A; López-Mínguez JR; Masotti M; Zueco J; Melgares R; Mainar V; Moreno R; Domínguez A; Sanchís J; Bethencourt A; Moreu J; Cequier A; Martí V; Otaegui I; Bastante T; Gonzalo N; Jiménez-Quevedo P; Cárdenas A; Fernández C;
    Circ Cardiovasc Interv; 2016 Jul; 9(7):. PubMed ID: 27412868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development and validation of a risk prediction nomogram for in-stent restenosis in patients undergoing percutaneous coronary intervention.
    He W; Xu C; Wang X; Lei J; Qiu Q; Hu Y; Luo D
    BMC Cardiovasc Disord; 2021 Sep; 21(1):435. PubMed ID: 34521385
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [The predictive value of epicardial adipose tissue and inflammatory factors for in-stent restenosis].
    Zhou QN; Lin WH; Jing R; Liu JJ; Shi HY; Yang RF; Gao P; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2019 Dec; 99(47):3732-3736. PubMed ID: 31874499
    [No Abstract]   [Full Text] [Related]  

  • 19. Prognostic values of C-reactive protein levels on clinical outcome after implantation of sirolimus-eluting stents in patients on hemodialysis.
    Ishii H; Toriyama T; Aoyama T; Takahashi H; Amano T; Hayashi M; Tanaka M; Kawamura Y; Yasuda Y; Yuzawa Y; Maruyama S; Matsuo S; Matsubara T; Murohara T
    Circ Cardiovasc Interv; 2009 Dec; 2(6):513-8. PubMed ID: 20031768
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of post-intervention minimal stent area on 9-month follow-up patency of paclitaxel-eluting stents: an integrated intravascular ultrasound analysis from the TAXUS IV, V, and VI and TAXUS ATLAS Workhorse, Long Lesion, and Direct Stent Trials.
    Doi H; Maehara A; Mintz GS; Yu A; Wang H; Mandinov L; Popma JJ; Ellis SG; Grube E; Dawkins KD; Weissman NJ; Turco MA; Ormiston JA; Stone GW
    JACC Cardiovasc Interv; 2009 Dec; 2(12):1269-75. PubMed ID: 20129555
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.